Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The impact of prior BCMA CAR-T therapy on the efficacy BCMA-targeting bispecifics in myeloma

Surbhi Sidana, MD, Stanford University, Stanford, CA, discusses the sequencing of BCMA-targeting CAR-T cells and bispecific antibodies in relapsed/refractory (R/R) multiple myeloma, commenting on the role of BCMA loss, and referencing data from recent clinical trials. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.